NEW YORK, April 30, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on SNN, SYK, VRAY, and ZBH which can be accessed for free by signing up to www.wallstequities.com/registration. This morning's research on WallStEquities.com is focused on the Medical Appliances and Equipment industry,
Smith & Nephew
London, the UK headquartered Smith & Nephew PLC's shares recorded a trading volume of 515,771 shares last Friday. The stock finished the trading session 0.03% lower at $39.10. The Company's shares have gained 1.69% in the last month, 5.14% over the previous three months, and 17.98% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.44% and 7.73%, respectively. Furthermore, shares of Smith & Nephew, which designs, develops, and sells medical devices worldwide, have a Relative Strength Index (RSI) of 63.62. Get the full research report on SNN for free by clicking below at:
On Friday, Kalamazoo, Michigan headquartered Stryker Corp.'s stock ended the session 1.52% higher at $170.67. A total volume of 1.82 million shares was traded, which was above their three months average volume of 1.32 million shares. The Company's shares have gained 8.04% in the last month, 1.04% over the previous three months, and 26.08% over the past year. The stock is trading 5.41% above its 50-day moving average and 11.18% above its 200-day moving average. Moreover, shares of Stryker, which operates as a medical technology company, have an RSI of 65.73.
On April 27th, 2018, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $183 a share to $187 a share. The free technical report on SYK can be accessed at:
Oakwood Village, Ohio headquartered ViewRay Inc.'s stock ended the day 0.93% lower at $7.49 with a total trading volume of 488,352 shares. The Company's shares have gained 14.18% in the last month and 13.83% over the past year. The stock is trading 2.28% above its 200-day moving average. Additionally, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have an RSI of 52.00. Sign up for free on Wall St. Equities and claim the latest report on VRAY at:
Zimmer Biomet Holdings
Shares in Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc. recorded a trading volume of 1.99 million shares, which was above their three months average volume of 1.30 million shares. The stock ended Friday's session 1.58% higher at $116.92. The Company's shares have gained 8.10% in the last month. The stock is trading above its 50-day moving average by 3.33%. Furthermore, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, EMEA region, and Asia/Pacific, have an RSI of 65.72.
On April 27th, 2018, research firm Needham reiterated its 'Strong Buy' rating on the Company's stock with a decrease of the target price from $155 a share to $146 a share. See the free research coverage on ZBH at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-medical-equipment-stocks----smith--nephew-stryker-viewray-and-zimmer-biomet-300638798.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Graviola''s health benefits range from curing headaches to fighting cancer. Read on to know more ...
Gene therapy is a specialized procedure where genetic material is introduced into the cells of a ...
The orange-like citrus fruit, Kumquat, is a complete health booster if included regularly in your ...View All